Point72 DIFC Ltd Purchases New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 23,698 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

Several other institutional investors have also made changes to their positions in MRNS. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $34,000. Values First Advisors Inc. raised its position in Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares in the last quarter. Hussman Strategic Advisors Inc. raised its position in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares in the last quarter. XTX Topco Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $232,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Marinus Pharmaceuticals during the first quarter valued at approximately $384,000. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Stock Performance

NASDAQ MRNS opened at $1.84 on Monday. The company has a market capitalization of $101.08 million, a price-to-earnings ratio of -0.70 and a beta of 1.13. Marinus Pharmaceuticals, Inc. has a twelve month low of $1.05 and a twelve month high of $11.26. The stock has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $2.57. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the previous year, the company earned ($0.61) earnings per share. Sell-side analysts expect that Marinus Pharmaceuticals, Inc. will post -1.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. StockNews.com downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Truist Financial reiterated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. JMP Securities reiterated a “market outperform” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Monday, September 23rd. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.83.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.